AbbVie releases phase 3 induction therapy data on injectable Skyrizi for Crohn's
AbbVie (ABBV) announced new findings from a phase 3 trial showing that the subcutaneous version of its drug Skyrizi, used to treat Crohn’s disease, achieved higher rates of endoscopic remission and ulcer-free endoscopy compared to placebo. The results were observed at week 24 of treatment. The data highlights Skyrizi's potential as an effective therapy for patients with moderate-to-severe Crohn’s disease, offering a convenient injectable option that could improve patient adherence and outcomes in real-world settings. These findings may support further regulatory approvals or label expansions for the drug. From a market perspective, positive phase 3 data can boost investor confidence in AbbVie's pipeline and reinforce its position as a leader in gastrointestinal therapeutics.
Tickers: $ABBV
Topics: Biotech Crohn's Disease Drug Development Pharma